Transaction in own shares

Arix intends to retain the purchased shares in treasury.

Metadata

Provider:

EQS

Retrieved on:

Friday, April 9, 2021

Information

Tags:

Equity securities, Financial economics, Finance, Money, Corporate finance, Common stock, Share

Geotags:

UK, LONDON

Summary

Key Points:

Arix intends to retain the purchased shares in treasury.
Following settlement of the above purchase, Arix will have 134,536,653 ordinary shares of 0.001 pence each in issue (excluding 1,073,000 ordinary shares of 0.001 pence each held in treasury).
In accordance with Article 5(1)(b) of Regulation (EU) No.
For more information on Arix, please contact:

Arix Bioscience PLC (ARIX)

Transaction in own shares

09-Apr-2021 / 17:43 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

Transaction in own shares

LONDON, 09 April 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

Date of purchase	09 April 2021
Aggregate number of shares purchased	92,000
Highest price paid per share	190.00p
Lowest price paid per share	190.00p
Average price paid per share	190.00p

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 134,536,653 ordinary shares of 0.001 pence each in issue (excluding 1,073,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

[email protected]

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
09/04/2021	08:24:42	46,000	190.00	London Stock Exchange	00233980151TRLO0
09/04/2021	10:15:57	46,000	190.00	London Stock Exchange	00234003953TRLO0


ISIN:	GB00BD045071
Category Code:	POS
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	2.4. Acquisition or disposal of the issuer's own shares
Sequence No.:	98242
EQS News ID:	1183207


End of Announcement	EQS News Service